These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 38809224

  • 21. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
    Sudunagunta S, Green D, Christley R, Dukes-McEwan J.
    J Vet Cardiol; 2019 Jun; 23():21-31. PubMed ID: 31174726
    [Abstract] [Full Text] [Related]

  • 22. Partial external mitral annuloplasty in dogs with myxomatous mitral valve degeneration and congestive heart failure: outcome in 9 cases.
    de Andrade JN, Christopher Orton E, Boon J, Nishimori CT, Olivaes C, Camacho AA.
    J Vet Cardiol; 2011 Sep; 13(3):197-201. PubMed ID: 21824833
    [Abstract] [Full Text] [Related]

  • 23. Change of Vertebral Left Atrial Size in Dogs With Preclinical Myxomatous Mitral Valve Disease Prior to the Onset of Congestive Heart Failure.
    Lee D, Yun T, Koo Y, Chae Y, Ku D, Chang D, Kang BT, Yang MP, Kim H.
    J Vet Cardiol; 2022 Aug; 42():23-33. PubMed ID: 35675727
    [Abstract] [Full Text] [Related]

  • 24. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2008 Aug; 22(5):1124-35. PubMed ID: 18638016
    [Abstract] [Full Text] [Related]

  • 25. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J, Gerlach N, Weber K, Klima A, Wess G.
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [Abstract] [Full Text] [Related]

  • 26. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
    Zhou Q, Wu Z, Li L, Zhou H, Chen Y, Guo S, Guo Y, Ma X, Zhang J, Feng W, Cui X, Qiu C, Xu M, Deng G.
    J Proteomics; 2023 Jun 30; 282():104924. PubMed ID: 37146676
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
    Mangkhang K, Punyapornwithaya V, Tankaew P, Pongkan W, Chattipakorn N, Boonyapakorn C.
    Pol J Vet Sci; 2018 Dec 30; 21(4):673-680. PubMed ID: 30605282
    [Abstract] [Full Text] [Related]

  • 29. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
    Valente C, Guglielmini C, Domenech O, Contiero B, Zini E, Poser H.
    PLoS One; 2020 Dec 30; 15(9):e0238440. PubMed ID: 32870923
    [Abstract] [Full Text] [Related]

  • 30. Iron parameters analysis in dogs with myxomatous mitral valve disease.
    Kumiega E, A Kobak K, Noszczyk-Nowak A, Kasztura M.
    BMC Vet Res; 2024 May 18; 20(1):210. PubMed ID: 38762716
    [Abstract] [Full Text] [Related]

  • 31. Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration.
    Pirintr P, Saengklub N, Limprasutr V, Sawangkoon S, Kijtawornrat A.
    J Vet Med Sci; 2017 Sep 12; 79(9):1480-1488. PubMed ID: 28717064
    [Abstract] [Full Text] [Related]

  • 32. Plasma and serum serotonin concentrations and surface-bound platelet serotonin expression in Cavalier King Charles Spaniels with myxomatous mitral valve disease.
    Cremer SE, Kristensen AT, Reimann MJ, Eriksen NB, Petersen SF, Marschner CB, Tarnow I, Oyama MA, Olsen LH.
    Am J Vet Res; 2015 Jun 12; 76(6):520-31. PubMed ID: 26000599
    [Abstract] [Full Text] [Related]

  • 33. Clinical relevance of serum ionized magnesium concentration in dogs with myxomatous mitral valve disease.
    Kim OK, Kim K, Park S, Yang H, Kim H, Ro WB, Lee CM.
    J Vet Intern Med; 2024 Jun 12; 38(1):41-50. PubMed ID: 38064361
    [Abstract] [Full Text] [Related]

  • 34. Untargeted metabolomic profiling of dogs with myxomatous mitral valve disease and congestive heart failure shows metabolic differences associated with the presence of cardiac cachexia.
    Freeman LM, Rush JE, Karlin ET.
    Am J Vet Res; 2023 Dec 01; 84(12):. PubMed ID: 38041949
    [Abstract] [Full Text] [Related]

  • 35. Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.
    Yata M, Kooistra HS, Beijerink NJ.
    J Vet Intern Med; 2019 Mar 01; 33(2):462-470. PubMed ID: 30703246
    [Abstract] [Full Text] [Related]

  • 36. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P.
    J Vet Intern Med; 2016 Nov 01; 30(6):1765-1779. PubMed ID: 27678080
    [Abstract] [Full Text] [Related]

  • 37. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease.
    Reimann MJ, Ljungvall I, Hillström A, Møller JE, Hagman R, Falk T, Höglund K, Häggström J, Olsen LH.
    Vet J; 2016 Mar 01; 209():113-8. PubMed ID: 26831162
    [Abstract] [Full Text] [Related]

  • 38. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
    Chanmongkolpanit K, Riengvirodkij N, Channgam P, Kaenchan P, Buayam W, Janhirun Y, Phonarknguen R, Tansakul M, Sakcamduang W.
    Open Vet J; 2024 Jun 01; 14(6):1426-1441. PubMed ID: 39055758
    [Abstract] [Full Text] [Related]

  • 39. Atrial Fibrillation as a Prognostic Indicator in Medium to Large-Sized Dogs with Myxomatous Mitral Valvular Degeneration and Congestive Heart Failure.
    Jung SW, Sun W, Griffiths LG, Kittleson MD.
    J Vet Intern Med; 2016 Jun 01; 30(1):51-7. PubMed ID: 26681398
    [Abstract] [Full Text] [Related]

  • 40. Anatomic regurgitant orifice area obtained using 3D-echocardiography as an indicator of severity of mitral regurgitation in dogs with myxomatous mitral valve disease.
    Müller S, Menciotti G, Borgarelli M.
    J Vet Cardiol; 2017 Oct 01; 19(5):433-440. PubMed ID: 28964709
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.